US industry concerned about FDA's data falsification rule
This article was originally published in SRA
The US pharmaceutical and clinical research industry has expressed serious concerns about a new rule proposed by the Food and Drug Administration, which, if finalised, would require sponsors to report to the agency about any individual who has, or may have, engaged in falsification of data in studies involving human or animal subjects1,2.
You may also be interested in...
Democratic senators push data-challenged gene therapy into maw of drug pricing debate as they press acting commissioner Sharpless to bring the hammer down on Novartis, but also question US FDA's decision to withdraw the proposed rule last year.
The European Medicines Agency has partnered with eight institutions having access to real-world healthcare data to enable its DARWIN EU project to deliver real-world evidence to the EU medicines regulatory network when needed.
Improvements have been made to the second phase of an EU pilot that allows drug sponsors to obtain simultaneous scientific advice from two member states.